Prescribing information


Support with metaboliser status genotyping prior to MAYZENT initiation.

Determining the metaboliser status of patients is the first step when prescribing MAYZENT1

  • MAYZENT is mainly metabolised by the CYP2C9 metaboliser 
  • Genotype test to identify specific variants of CYP2C9, the principal enzyme that metabolises MAYZENT. Certain genotype variants of this enzyme metabolise MAYZENT more slowly than others
    –  required to determine suitability for MAYZENT and the appropriate maintenance dose
  • Patients with the CYP2C9*1/*3 or CYP2C9*2/*3 genotype should be prescibed 1 mg/day to avoid increased exposure to MAYZENT

MayzentConnect will help you to determine the metaboliser status of your patient and, if appropriate, to proceed and choose the appropriate dose.

We can provide you with:

  • The appropriate packaging and postage that is compliant with UK regulations to send the sample to Viapath Analytics LLP
  • Laboratory services to determine the CYP2C9 variation of each patient. The results will be sent back to you within 7 working days, from when Viapath Analytics LLP receive the sample


Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1

SPMS, secondary progressive multiple sclerosis.


  1. MAYZENT Summary of Product Characteristics. January 2021.
  2. Scott SA et al. Pharmacogenomics. 2010;11(6):781‒791.
  3. Kirchheiner J and Brockmoller J. Clin Pharmacol Ther. 2005;77(1):1‒16.
  4. Gaikwad T et al. Thromb Res. 2014;134(3):537‒544.
Rate this content: 
No votes yet
UK | May 2021 | 124689

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]